Ayodeji Adegunsoye

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5753440/publications.pdf

Version: 2024-02-01

68 papers 2,218 citations

201575 27 h-index 243529 44 g-index

71 all docs

71 docs citations

71 times ranked

2248 citing authors

#	Article	IF	CITATIONS
1	Racial Disparities in Pulmonary Fibrosis and the Impact on the Black Population. Archivos De Bronconeumologia, 2022, 58, 590-592.	0.4	5
2	Lung function trajectory in progressive fibrosing interstitial lung disease. European Respiratory Journal, 2022, 59, 2101396.	3.1	40
3	Interstitial Lung Disease in Firefighters: An Emerging Occupational Hazard. Frontiers in Medicine, 2022, 9, 864658.	1.2	6
4	Inhaled Nitric Oxide for Fibrotic Interstitial Lung Disease: A Step Forward. Annals of the American Thoracic Society, 2022, 19, 536-538.	1.5	4
5	Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp> . Respirology, 2022, 27, 635-644.	1.3	12
6	Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest, 2022, 162, 614-629.	0.4	19
7	Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. European Respiratory Journal, 2021, 57, 2002872.	3.1	32
8	Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 197-208.	2.5	27
9	Anticoagulation and Pulmonary Fibrosis. Chest, 2021, 159, 1321-1323.	0.4	O
10	Vessel-related structures predict UIP pathology in those with a non-IPF pattern on CT. European Radiology, 2021, 31, 7295-7302.	2.3	10
11	A series of <scp>COVID</scp> â€19 autopsies with clinical and pathologic comparisons to both seasonal and pandemic influenza. Journal of Pathology: Clinical Research, 2021, 7, 459-470.	1.3	9
12	Molecular pathways in idiopathic pulmonary fibrosis pathogenesis: Transcending barriers to optimally targeted pharmacotherapies. EBioMedicine, 2021, 67, 103373.	2.7	1
13	Diagnostic Classification of Interstitial Lung Disease in Clinical Practice. Clinics in Chest Medicine, 2021, 42, 251-261.	0.8	6
14	Differentiation of Idiopathic Pulmonary Fibrosis from Connective Tissue Disease-Related Interstitial Lung Disease Using Quantitative Imaging. Journal of Clinical Medicine, 2021, 10, 2663.	1.0	11
15	Characteristics and Prevalence of Domestic and Occupational Inhalational Exposures Across Interstitial Lung Diseases. Chest, 2021, 160, 209-218.	0.4	18
16	Association of antinuclear antibody seropositivity with inhaled environmental exposures in patients with interstitial lung disease. ERJ Open Research, 2021, 7, 00254-2021.	1.1	0
17	Risk, Race, and Structural Racism. Annals of the American Thoracic Society, 2021, 18, 1289-1290.	1.5	1
18	The Progression to Interstitial Lung Disease. Chest, 2021, 160, 400-402.	0.4	4

#	Article	IF	Citations
19	Hospitalizations in patients with idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 257.	1.4	8
20	Treatment of fibrotic interstitial lung disease: current approaches and future directions. Lancet, The, 2021, 398, 1450-1460.	6.3	47
21	Rituximab for interstitial pneumonia with autoimmune features at two medical centres. Rheumatology Advances in Practice, 2021, 5, ii1-ii9.	0.3	7
22	High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease. Scientific Reports, 2021, 11, 22821.	1.6	8
23	Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 250-253.	2.5	30
24	Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 564-574.	2.5	208
25	Association of Black Race with Outcomes in COVID-19 Disease: A Retrospective Cohort Study. Annals of the American Thoracic Society, 2020, 17, 1336-1339.	1.5	44
26	Myositis-specific antibodies identify a distinct interstitial pneumonia with autoimmune features phenotype. European Respiratory Journal, 2020, 56, 2001205.	3.1	24
27	Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Advances, 2020, 4, 4873-4886.	2.5	23
28	Automated CT Analysis of Major Forms of Interstitial Lung Disease. Journal of Clinical Medicine, 2020, 9, 3776.	1.0	14
29	Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest, 2020, 158, 1526-1534.	0.4	31
30	CPAP Adherence, Mortality, and Progression-Free Survival in Interstitial Lung Disease and OSA. Chest, 2020, 158, 1701-1712.	0.4	19
31	Rare Protein-Altering Telomere-related Gene Variants in Patients with Chronic Hypersensitivity Pneumonitis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1154-1163.	2.5	81
32	Prevalence and Clinical Significance ofÂAntineutrophil Cytoplasmic Antibodies inÂNorth American Patients With Idiopathic Pulmonary Fibrosis. Chest, 2019, 156, 715-723.	0.4	45
33	Diagnostic test interpretation and referral delay in patients with interstitial lung disease. Respiratory Research, 2019, 20, 253.	1.4	35
34	Diagnostic Delay in Idiopathic Pulmonary Fibrosis: Where the Rubber Meets the Road. Annals of the American Thoracic Society, 2019, 16, 310-312.	1.5	2
35	Integrating Genomics Into Management ofÂFibrotic Interstitial Lung Disease. Chest, 2019, 155, 1026-1040.	0.4	37
36	MUC5B promoter variant: genomic fingerprint for early identification of undiagnosed pulmonary fibrosis. Thorax, 2019, 74, 1111-1112.	2.7	2

#	Article	IF	Citations
37	Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 747-759.	2.5	36
38	Anti-RNA binding protein positivity in idiopathic interstitial pneumonia. Respiratory Medicine, 2019, 146, 23-27.	1.3	1
39	Reply to Lescoat et al. and to Khamis et al American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1041-1042.	2.5	0
40	Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases. Annals of the American Thoracic Society, 2019, 16, 580-588.	1.5	93
41	Telomere length and genetic variant associations with interstitial lung disease progression and survival. European Respiratory Journal, 2019, 53, 1801641.	3.1	119
42	African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis. European Respiratory Journal, 2018, 51, 1800255.	3.1	37
43	Underreporting of Interstitial Lung Abnormalities on Lung Cancer Screening Computed Tomography. Annals of the American Thoracic Society, 2018, 15, 764-766.	1.5	30
44	CT-Pathologic Correlation of Major Types of Pulmonary Fibrosis: Insights for Revisions to Current Guidelines. American Journal of Roentgenology, 2018, 210, 1034-1041.	1.0	26
45	ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunology, 2018, 11, 61-70.	2.7	23
46	Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort. Chest, 2018, 153, 349-360.	0.4	40
47	CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Disease–Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. American Journal of Roentgenology, 2018, 210, 307-313.	1.0	98
48	N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia. BMC Pulmonary Medicine, 2018, 18, 30.	0.8	5
49	Interstitial Pneumonia With Autoimmune Features: Value of Histopathology. Archives of Pathology and Laboratory Medicine, 2017, 141, 960-969.	1.2	29
50	CT Findings, Radiologic-Pathologic Correlation, and Imaging Predictors of Survival for Patients With Interstitial Pneumonia With Autoimmune Features. American Journal of Roentgenology, 2017, 208, 1229-1236.	1.0	47
51	De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. Chest, 2017, 152, 683-685.	0.4	12
52	Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Research, 2017, 3, 00016-2017.	1.1	84
53	CT findings associated with survival in chronic hypersensitivity pneumonitis. European Radiology, 2017, 27, 5127-5135.	2.3	41
54	Comprehensive Care of the Lung Transplant Patient. Chest, 2017, 152, 150-164.	0.4	74

#	Article	IF	CITATIONS
55	Autoimmune Hypothyroidism As a Predictor of Mortality in Chronic Hypersensitivity Pneumonitis. Frontiers in Medicine, 2017, 4, 170.	1.2	10
56	Skewed Lung CCR4 to CCR6 CD4+ T Cell Ratio in Idiopathic Pulmonary Fibrosis Is Associated with Pulmonary Function. Frontiers in Immunology, 2016, 7, 516.	2.2	29
57	A call for uniformity in implementing the IPAF (interstitial pneumonia with autoimmune features) criteria. European Respiratory Journal, 2016, 48, 1813-1814.	3.1	8
58	Predictors of survival in coexistent hypersensitivity pneumonitis with autoimmune features. Respiratory Medicine, 2016, 114, 53-60.	1.3	42
59	Characterisation of patients with interstitial pneumonia with autoimmune features. European Respiratory Journal, 2016, 47, 1767-1775.	3.1	219
60	Imaging of Hypersensitivity Pneumonitis. Radiologic Clinics of North America, 2016, 54, 1033-1046.	0.9	34
61	Therapeutic Approach to Adult Fibrotic Lung Diseases. Chest, 2016, 150, 1371-1386.	0.4	39
62	Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respiratory Medicine, 2016, 121, 117-122.	1.3	85
63	Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. BioMed Research International, 2015, 2015, 1-16.	0.9	5
64	Inflammatory Response Mechanisms Exacerbating Hypoxemia in Coexistent Pulmonary Fibrosis and Sleep Apnea. Mediators of Inflammation, 2015, 2015, 1-13.	1.4	27
65	Etiopathogenetic Mechanisms of Pulmonary Hypertension in Sleep-Related Breathing Disorders. Pulmonary Medicine, 2012, 2012, 1-10.	0.5	27
66	A 20-year-old woman with rapidly progressive dyspnea and diffuse pulmonary infiltrates. Respiratory Medicine Case Reports, 2012, 5, 34-36.	0.2	6
67	The role of echocardiography in the evaluation and management of aortic stenosis in the older adult. International Journal of Cardiology, 2012, 155, 39-48.	0.8	6
68	Echocardiographic Evaluation of Calcific Aortic Stenosis in the Older Adult. Echocardiography, 2011, 28, 117-129.	0.3	16